Avalyn Pharma Inc. (AVLN)
AVLN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AVLN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2026 |
| SEC CIK | 0001540171 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
New registrant: no annual report filed under this company yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Going Concern The Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the consolidated financial statements are issued." | 10-Q 2026-11-12 |
| Cash and burn | $145.4M cash; operating cash flow -$24.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 44,521,494 (2026-11-10). | Cover page 2026-11-10 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-28 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $20.0M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$29.7M | -$26.3M | $145.4M | $14.8M | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-06-30 | Not filed | -$28.9M | -$26.1M | $264.2M | $14.8M | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2026-03-31 | Not filed | -$26.9M | -$29.9M | $92.3M | $14.8M | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-09-30 | Not filed | -$23.6M | -$17.3M | $27.6M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-06-30 | Not filed | -$20.2M | -$20.7M | $61.3M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
| Q3 2026 2025-03-31 | Not filed | -$17.5M | -$19.3M | $28.8M | No debt tags | Needs four quarters | 10-Q 2026-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2026-04-30 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report | 8-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 66 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.9% |
| 1 month | +27.5% |
| 3 months | -17.2% |
| Year to date | Not enough price history |
| 1 year | Not enough price history |
| From 52-week high | -22.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OCUL | Ocular Therapeutix Inc. | $6.01 | -3.22% | $1.3B |
| GPCR | Structure Therapeutics Inc. | $18.57 | -7.15% | $1.3B |
| INVA | Innoviva Inc. | $18.49 | -2.84% | $1.3B |
| GENB | Generate Biomedicines Inc. | $10.49 | -13.09% | $1.4B |
| NUVB | Nuvation Bio Inc. | $3.84 | -3.76% | $1.4B |
| ANAB | AnaptysBio Inc. | $45.73 | -1.12% | $1.4B |
| TYRA | Tyra Biosciences Inc. | $19.74 | -1.42% | $1.4B |
| MLYS | Mineralys Therapeutics Inc. | $14.53 | -5.22% | $1.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier